摘要:
The present invention relates to a compound represented by formula (1): (wherein R represents a hydrogen atom or a C1-6 alkyl group which may be substituted, A represents an imidazolyl group or a pyrazolyl group, B represents a group represented by the following formula: (wherein R5 and R6 each independently represents a hydrogen atom, a cyano group, a hydroxyl group, a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, or the like, k represents 0 or an integer of 1 to 15, and R5 and R6 may be identical or different from each other, when k is 2 or more), and Z represents a substituted chroman-2-yl group, a substituted 2,3-dihydrobenzofuran-2-yl, a substituted thiochroman-2-yl group, a substituted 2,3-dihydrobenzothiophene-2-yl group, or a substituted 1,3-benzoxathiol-2-yl group).
摘要:
The present invention is directed to compounds represented by the formula (1):B-D-Z (1), wherein B represent the following formula (B-1), A represents an optionally substituted imidazole or pyrazole group; E represents the following formula (1a): X represents an oxygen atom, the formula: SOu, or the formula: N—R9; Y represents a carbon atom or a nitrogen atom; D represents an oxygen atom, a sulfur atom or the formula (1a); Z represents (a chroman-2-yl group, a chroman-4-yl group, a 2,3-dihydrobenzofuran-2-yl group, a 2,3-dihydrobenzofuran-3-yl group, etc.) which is substituted with NHR10 or OR11)] or pharmaceutically acceptable salts thereof, and to antioxidants, therapeutic agents for kidney diseases or cerebrovascular disorder, and retinal oxidative damage inhibitors, which include the compounds as the active ingredient.
摘要:
The present invention relates to a compound represented by formula (1): (wherein, R1, R2, R3 and R4 respectively and independently represent a hydrogen atom or a C1-6 alkyl group, and n represents an integer of 1 or 2) and a production process thereof, as well as an antioxidant that contains the compound as its active ingredient, and a kidney disease treatment agent, cerebrovascular disorder treatment agent, retina oxidative disorder inhibitor and lipoxygenase inhibitor that contain the antioxidant.
摘要:
The present invention is directed to compounds represented by the formula (1): B-D-Z (1), wherein B represent the following formula (B-1), (B-2) or (B-3); A represents an optionally substituted imidazole or pyrazole group; E represents the following formula (1a); X represents an oxygen atom, the formula: SOu, or the formula: N—R9; Y represents a carbon atom or a nitrogen atom; D represents an oxygen atom, a sulfur atom or the formula (1a); Z represents (a chroman-2-yl group, a chroman-4-yl group, a 2,3-dihydrobenzofuran-2-yl group, a 2,3-dihydrobenzofuran-3-yl group, etc.) which is substituted with NHR10 or OR11)] or pharmaceutically acceptable salts thereof, and to antioxidants, therapeutic agents for kidney diseases or cerebrovascular disorder, and retinal oxidative damage inhibitors, which include the compounds as the active ingredient.
摘要:
The present invention relates to a compound represented by formula (1): (wherein, R1, R2, R3 and R4 respectively and independently represent a hydrogen atom or a C1-6 alkyl group, and n represents an integer of 1 or 2) and a production process thereof, as well as an antioxidant that contains the compound as its active ingredient, and a kidney disease treatment agent, cerebrovascular disorder treatment agent, retina oxidative disorder inhibitor and lipoxygenase inhibitor that contain the antioxidant.
摘要:
Phenylazole compounds represented by general formula (1) or pharmaceutically acceptable salts thereof and drugs for hyperlipemia which contain these compounds as the active ingredient, wherein A represents imidazolyl, pyrazolyl, etc.; B represents (1a) or (1b) (wherein R2 and R3 represent each hydrogen, C1-6 alkyl, etc; and k is 0 or an integer of 1 to 15); Y represents O, S, a bond, etc.; and Z represents an optionally substituted and saturated or unsaturated heterocycle containing 1 to 4 N, O or S atoms. Among all, compounds wherein Z is substituted chroman-2-yl, 2,3-dihydrobenzofuran-2-yl, etc. have an effect of inhibiting the formation of lipid peroxides too.
摘要:
The present invention is directed to (R)-(-)-4,5-dihydro-5-methyl-6-�4-�(2-propyl-3-oxo-1-cyclohexenyl)amino!phenyl!-3(2H)-pyridazinone, the crystalline form thereof and a method for manufacturing the said compound and the said crystalline form.The compound of the present invention has excellent inhibitory effect on platelet aggregation while giving less side effect, and therefore, it is useful to utilize the compound as an antithrombotic drug. In addition, the compound of the present invention has bronchodialatic effect as well, and it is therefore useful to utilize the compound for chemotherapy of chronic obstructive lung disease, such as asthma and bronchitis.Moreover, the compound of the present invention is useful for chemotherapy of the diseases relating to the concentration of cAMP in cells, such as hypertension, ulcer, diabetes mellitus and cancer.Again, crystalline form of the said compound is the most suitable form in order to supply stable and homogeneous bulk thereof.
摘要:
The present invention is directed to compounds represented by the formula (1): B-D-Z (1) [wherein B represent the following formula (B-1), (B-2) or (B-3); A represents an optionally substituted imidazole or pyrazole group; E represents the following formula (1a): X represents an oxygen atom, the formula: SOu, or the formula: N—R9; Y represents a carbon atom or a nitrogen atom; D represents an oxygen atom, a sulfur atom or the formula (1a); Z represents (a chroman-2-yl group, a chroman-4-yl group, a 2,3-dihydrobenzofuran-2-yl group, a 2,3-dihydrobenzofuran-3-yl group, etc.) which is substituted with NHR10 or OR11)] or pharmaceutically acceptable salts thereof, and to antioxidants, therapeutic agents for kidney diseases or cerebrovascular disorder, and retinal oxidative damage inhibitors, which include the compounds as the active ingredient.
摘要:
Thieno[2,3-d]pyrimidine compounds of general formula (1) useful as drugs having a cGMP-specific phosphodiesterase inhibiting effect and the preparation thereof wherein Q is formula: (CH2)n—N(r1)—C(r2) (r3), CH═CH—CH═CH, or (CH2)m which is bonded to a and b; R1 is hydrogen or C1-C6 alkyl; R2 is C3-C8 cycloalkyl optionally substituted with G1, phenyl optionally substituted with G2, or a saturated or unsaturated heterocyclic group having 1 to 4 heteroatoms selected from N, O and S and being optionally substituted with G3; and R3 is a saturated or unsaturated heretocyclic group having 1 to 4 heteroatoms selected from N, O and S and being optionally substituted with G3 or (CH2)kC(═O)R4 or CH═CHC(O)R4.
摘要:
A preventive agent for platelet aggregation comprising a compound represented by the following general formula [I]: ##STR1## wherein Y is --CH.sub.2 CH.sub.2 -- or --CH.sub.2 CH.sub.2 CH.sub.2 --, R is hydrogen or methyl, and ---------- represents a single bond or a double bond, or a pharmaceutically-compatible complex thereof as the active ingredient, is disclosed.